Appropriate studies performed to date have not demonstrated geriatric -specific problems that would limit the usefulness of glipizide in the elderly . However, elderly patients are more likely to have age-related heart, liver, or kidney problems which may require caution in patients receiving glipizide .
“In these patients, we now know that glimepiride appears to be safer than the other commonly prescribed sulfonylureas, glipizide and glyburide, available in the United States.”
Amaryl ( glimepiride ) and Glucotrol ( glipizide ) are oral diabetes medicines of the sulfonylurea class used together with diet and exercise to treat type 2 (non-insulin dependent) diabetes.
HbA1c reduction in gliclazide and glimepiride group was 2.44 and 1.91 respectively. Conclusion: Gliclazide was found to be superior in terms of safety and efficacy. Hence it can be concluded from the study that gliclazide is a better option in diabetes when compared to glimepiride .
For those with a contraindication or intolerance to metformin, a short-acting sulfonylurea like glipizide is recommended as initial therapy. Long-acting sulfonylureas like chlorpropamide , glyburide , and glimepiride aren’t recommended for older patients due to increased risk for hypoglycemia.
Taken together, glibenclamide can result in sustained insulin release for protracted periods even after the drug is discontinued. Patients with renal impairment, as well as the elderly with age-related decline in renal function, would be at a greater risk of developing severe, long-lasting hypoglycaemia.
Glipizide can cause low blood sugar (hypoglycemia). If you don’t treat low blood sugar, you can have a seizure, pass out, and possibly develop brain damage. Low blood sugar can even be fatal.
Metformin is still the safest and most effective type 2 diabetes medication, said Bolen. She is an assistant professor of medicine at Case Western Reserve University’s Center for Health Care Research and Policy, in Cleveland.
Previous research indicates that the diabetes drugs sitagliptin and glipizide may not cause considerable kidney damage. New clinical trial results presented during the American Society of Nephrology’s Annual Kidney Week compared the two drugs.
Warnings for people with certain health conditions For people with kidney disease: Glimepiride is removed from your body by your kidneys . If your kidneys aren’t working as well, glimepiride may build up in your body and cause low blood sugar.
COMMON side effects Constipation . Diarrhea . Dizziness. Drowsiness. Gas. Headache . Muscle Tremors. Nausea .
According to a double-blind, clinical trial, metformin showed a greater cardioprotective effect than glipizide after a period of five years. Another comparative trial found that metformin provided better blood sugar control than glipizide .
Glipizide may also cause other effects related to blood sugar control outside of the pancreas . Glipizide belongs to a class of drugs known as sulfonylureas.
Gliclazide is a medicine used to treat type 2 diabetes . Type 2 diabetes is an illness where the body does not make enough insulin, or the insulin that’s made does not work properly. This causes high blood sugar (hyperglycaemia). Gliclazide lowers your blood sugar by increasing the amount of insulin your body produces.
In CKD sage 1, 2, 3 (eGFR > 30 mL/min) gliclazide can be used. There are no data in patients with severe CKD but according to its metabolism the use (in reduced dose) of gliclazide is also permitted in these subjects.